LinkedIn Profile

Access Pathway Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:pathwaytherapeutics 308945 May 31st, 2019 12:00AM Pathway Therapeutics Ltd 98 0.00 Open Biotechnology May 30th, 2019 08:47PM May 30th, 2019 08:47PM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Open Oncology Drug Development, Cancer Biology, PI3K/mTOR Pathway Inhibitors 409 Illinois Street San Francisco Ca US 94158 Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Mar 23rd, 2018 12:00AM Pathway Therapeutics Ltd 91 0.00 Open Biotechnology Mar 23rd, 2017 10:51AM Mar 23rd, 2017 10:51AM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 17th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 16th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 15th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 14th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 13th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 12th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 11th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services
private:pathwaytherapeutics 308945 Feb 10th, 2018 12:00AM Pathway Therapeutics Ltd 93 0.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors. Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration. Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months. Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA. Pathway Therapeutics Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.